No product marketed as peptide therapy is FDA approved for longevity or anti-aging. At Longevity Benchmark, we read the federal tables and the approved labels rather than the vendor copy. Among seven common molecules promoted in clinics and online forums, only one has an approved drug product for a single narrow medical indication. One molecule sits on the current federal restricted-compounding list under active safety scrutiny. Nominations for four other molecules were placed on that list and subsequently withdrawn by the original nominators. The seventh molecule appears on no federal compounding list at all. Federal regulatory records from the Food and Drug Administration (FDA) establish exact administrative classifications for compounding pharmacies, but these lists do not establish clinical efficacy for unapproved uses.
The Verdict
Peptide Therapy FDA Approved Status across Seven Molecules
No product marketed under the broad banner of peptide therapy holds FDA approval for anti-aging or general wellness. The legal status varies by molecule. Among the seven molecules evaluated here, only bremelanotide possesses an approved drug application. It is sold under the brand name Vyleesi for a specific female sexual dysfunction indication. The remaining six substances have no approved human drug products on the market. Compounding positions differ widely.
GHRP-6 sits on the active Category 2 restrictions table for 503B outsourcing facilities. In contrast, KPV, dihexa acetate, emideltide, and AOD-9604 sit on the separate table of withdrawn nominations. IGF-1 DES appears on neither table. Inquiries comparing growth hormone secretagogues like sermorelin versus ipamorelin involve distinct market dynamics addressed separately on this site. The following table outlines the current federal standing and highest evidence tier for each compound.
| Peptide | Approved product? | Position on FDA's compounding bulks lists | Highest tier of evidence that exists |
|---|---|---|---|
| PT-141 (bremelanotide) | Yes (marketed as Vyleesi) | Appears on neither table | Completed registration programme and an approved label |
| KPV | No | Withdrawn table | Mouse colitis models and cell assays |
| Dihexa acetate | No | Withdrawn table | Rodent cognition models |
| Emideltide (DSIP) | No | Withdrawn table (listed under emideltide) | Small human insomnia studies from the 1980s and 1990s |
| GHRP-6 | No | Active Category 2 table (503B) | Small human endocrine studies measuring hormone release |
| AOD-9604 | No | Withdrawn table | Animal lipid-metabolism studies |
| IGF-1 DES | No | Appears on neither table | Cell-culture potency work and animal studies |
Compounding Risk Categories and Withdrawn Nomination Tables
Federal oversight of compounded drug substances relies on distinct administrative categories that separate active restrictions from withdrawn nominations. The underlying federal records move over time. The regulatory page titled Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks was current as of 22 April 2026. This federal document contains two separate tables. The primary table lists bulk drug substances under Category 2 of the interim policies. The second table records bulk drug substances nominated but withdrawn. These classifications govern pharmacy bulk compounding rather than commercial drug approval.
Compounding channels follow distinct statutory definitions. Section 503A refers to compounding by a licensed pharmacy for an identified individual patient. Section 503B designates an outsourcing facility. A substance in Category 2 under one section is restricted only for that specific compounding channel.
Withdrawn status requires careful interpretation. A substance on the withdrawn table sits on neither active compounding list. It is not in the active Category 2 restrictions table. It is also not on any list of bulk substances permitted for compounding. Withdrawal does not indicate that a substance is cleared, permitted, or banned by federal regulators. The agency page does not define what withdrawal means for an individual pharmacy or buyer.
Compounding tables differ fundamentally from commercial approvals. An approved drug follows a separate regulatory route from bulk compounding. A molecule with an approved drug product has no administrative reason to appear on either compounding table.
PT-141 Bremelanotide and Its Single Approved Indication
PT-141, known generic bremelanotide, is the only molecule on this page with an approved human drug application. The compound is marketed as Vyleesi. It functions as a melanocortin receptor agonist. According to the official DailyMed label, the product is indicated solely for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).
Strict limitations of use define the boundary of this approval. The label states verbatim: "Not indicated for treatment of HSDD in postmenopausal women or in men. Not indicated to enhance sexual performance." The medication is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease. PT-141 appears on neither compounding table. Approved drugs follow standard commercial manufacturing rather than bulk pharmacy compounding pathways.
Detailed trial outcomes appear in our review of PT-141 evidence and trial results. This molecule holds the highest evidentiary tier on this page through a completed registration program.
GHRP-6 and Federal Category 2 Safety Restrictions
GHRP-6 is the only molecule on this page currently placed in Category 2 on federal compounding lists. The restriction took effect in autumn 2023. Regulators added GHRP-6 to Category 2 for 503B outsourcing facilities on 29 September 2023.
In its safety assessment, FDA stated verbatim that compounded drugs containing GHRP-6 "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities." The agency added: "FDA has identified limited safety-related information, but the available data reveal safety concerns including potential effect on cortisol and increase in blood glucose due to decreases in insulin sensitivity." GHRP-6 has no approved drug product. It acts on the growth hormone secretagogue receptor GHS-R1a, the receptor that ghrelin binds.
Endocrine research supports the agency's specific physiological concerns. A 1995 clinical study evaluated repeated intravenous boluses during sleep in seven healthy young men. The investigators reported acute increases in growth hormone, ACTH, and cortisol. This measured human increase in cortisol directly mirrors the specific endocrine safety concern highlighted by federal regulators. The highest evidence tier for GHRP-6 consists of small endocrine studies measuring hormone release rather than clinical outcomes.
Four Withdrawn Nominations and Missing Human Exposure Data
Four molecules promoted in clinical wellness protocols previously sat in Category 2 before their nominators withdrew the submissions. These compounds are KPV, dihexa acetate, emideltide, and AOD-9604. None of these four substances has an approved drug product.
FDA stated verbatim: "FDA has not identified any human exposure data on drug products containing KPV administered via any route of administration." The agency continued: "FDA lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans." KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. Its published evidence base rests on mouse colitis models and cell assays, evaluated further in our report on KPV peptide evidence.
Dihexa acetate shares a similar regulatory profile. For dihexa acetate, an angiotensin IV analogue acting via the hepatocyte growth factor and c-Met system, the agency published identical language confirming an absence of human exposure data. Rodent cognition models represent its highest published evidence tier, detailed in our summary of dihexa research and models.
Emideltide requires naming clarification. Emideltide appears on the withdrawn table under that generic title, representing delta sleep-inducing peptide (DSIP). Readers searching for the DSIP acronym will not locate the compound on the agency page without referencing emideltide. FDA stated verbatim that compounded drugs containing emideltide "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization." The agency added: "FDA has not identified safety-related information regarding emideltide for the proposed route of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans." Small human insomnia studies from the 1980s and 1990s evaluated the peptide. Trial authors characterized the observed sleep benefits as clinically insignificant, as reviewed in our analysis of DSIP peptide evidence.
AOD-9604 presents distinct regulatory findings. FDA stated verbatim that compounded drugs containing AOD-9604 "may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization." The assessment continued: "FDA has identified no, or only limited, safety-related information. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans." Regulators noted: "FDA has also identified serious adverse events that may be associated with AOD-9604, though causality is not clear."
Chemical naming requires exact precision. The molecule sold under the title fragment 176-191 is a C-terminal fragment of human growth hormone. According to the National Library of Medicine MeSH record, AOD-9604 is an N-tyrosyl analog of that lipolytic fragment. It contains the 177-191 sequence with a tyrosine added at the N-terminus. Fragment 176-191 under that exact phrase appears on neither federal compounding table. AOD-9604 sits on the withdrawn table. Animal lipid metabolism studies represent the highest tier of data for AOD-9604.
IGF-1 DES and the Contrast with Approved Mecasermin
IGF-1 DES is completely absent from federal compounding tables and possesses no approved drug product. This regulatory status provides a contrast with full-length recombinant IGF-1, which holds full commercial approval. Mecasermin, marketed as Increlex, is an approved drug product.
The official Increlex label on DailyMed defines clear boundaries. The medication is indicated for the treatment of growth failure in pediatric patients two years of age and older with severe primary IGF-1 deficiency or growth hormone gene deletion who developed neutralizing antibodies. Limitations of use state verbatim: "INCRELEX is not a substitute to GH for approved GH indications."
IGF-1 DES represents a truncated peptide sequence known as des(1-3)IGF-I. A 1996 scientific review noted that this truncated sequence is roughly tenfold more potent than full-length IGF-I in cell culture assays. The authors attributed this difference to substantially weaker binding to IGF-binding proteins. That same review explicitly stated that clinical opportunities for the truncated molecule had not yet been evaluated in human subjects. The highest tier of evidence for IGF-1 DES remains limited to cell-culture potency assays and preliminary animal research. Full-length mecasermin achieved market approval through dedicated clinical trials, while truncated IGF-1 DES has never undergone human registration.
Unsettled Legal Questions behind Peptide Therapy FDA Approved Claims
Federal compounding tables address bulk pharmacy handling rather than clinical legitimacy or broad statutory legality. The federal tables current as of 22 April 2026 reflect an administrative snapshot subject to periodic regulatory updates. Readers should verify current listings directly on the FDA page. The presence or absence of a substance on these tables does not establish whether a clinic may lawfully administer it in every local jurisdiction. Furthermore, no regulatory body has approved any peptide product for longevity, life extension, or general anti-aging.
Other peptides sit on these tables alongside the primary seven compounds. The active Category 2 restrictions table includes injectable and nasal GHRP-2 (503B added 29 September 2023), ibutamoren mesylate (503A added 29 September 2023 and 503B added 29 December 2022), and kisspeptin-10 (503A added 29 September 2023). Nominations on the withdrawn table include BPC-157, CJC-1295, epitalon, injectable GHK-Cu, melanotan II, MOTS-c, PEG-MGF, selank acetate, semax, thymosin alpha-1, and the thymosin beta-4 fragment TB-500.
Patients evaluating clinical proposals can examine general market pricing dynamics in our review of peptide therapy costs or contrast standard medical therapies in our breakdown of peptide therapy versus GLP-1 medications. Federal bulk lists remain technical compounding boundaries rather than complete legal determinations.
Frequently Asked Questions
Is peptide therapy FDA approved?
No product sold under the label of peptide therapy is FDA approved for longevity, anti-aging, or wellness. Certain individual peptide molecules carry approvals for distinct medical conditions. For example, bremelanotide (marketed as Vyleesi) holds an approved drug label for premenopausal women with hypoactive sexual desire disorder. Similarly, mecasermin (Increlex) is approved for severe pediatric growth failure resulting from primary IGF-1 deficiency. Neither approval covers longevity or anti-aging. Regulators evaluate specific drug formulations for defined disease indications rather than clearing broad categories like peptide therapy.
Is peptide therapy legal?
The legal status of peptide therapy depends on the specific chemical compound, the manufacturing route, and state medical licensing rules. Federal compounding lists restrict certain bulk substances, placing compounds like GHRP-6 under Category 2 safety restrictions for 503B outsourcing facilities. Other substances, such as KPV, dihexa acetate, and emideltide, have had their compounding nominations withdrawn by the original nominators. Federal lists govern whether pharmacies can compound drugs from bulk substances under sections 503A and 503B. These federal administrative tables do not resolve whether a licensed physician can prescribe an unapproved compound in a specific state.
Where is peptide therapy legal?
Federal compounding lists do not settle state-level or practice-level legal questions. The Food and Drug Administration maintains lists designating bulk drug substances that present potential safety risks under sections 503A and 503B. However, federal agency documentation current as of 22 April 2026 does not delineate state-by-state legality for clinical administration. A compound restricted for bulk compounding at an outsourcing facility may face different local distribution rules than one prepared for an individual patient.
Does peptide therapy require a prescription?
The federal compounding lists, current as of 22 April 2026, settle neither state-level nor practice-level prescription rules.
Is peptide therapy legit?
The legitimacy of peptide therapy varies entirely by the specific molecule, its regulatory approval status, and the underlying scientific evidence. Individual peptide drugs backed by completed clinical registration programs, such as bremelanotide, possess demonstrated safety and efficacy for their approved indications. Conversely, many substances promoted in commercial clinics have never undergone human safety trials. For compounds like KPV and dihexa acetate, federal regulators have noted a complete absence of human exposure data. Scientific evidence for other molecules is confined to animal models or preliminary laboratory assays. Promoting unapproved peptides for anti-aging relies on speculative extrapolation rather than verified clinical proof.
Which peptides are FDA approved?
Among the compounds commonly cited in clinical wellness discussions, only PT-141 (bremelanotide) holds an approved drug application, sold as Vyleesi for premenopausal hypoactive sexual desire disorder. Outside this specific group, full-length recombinant IGF-1 (mecasermin, sold as Increlex) holds approval for pediatric growth failure. Beyond these examples, widely promoted substances like GHRP-6, KPV, dihexa acetate, emideltide, AOD-9604, and IGF-1 DES have no approved human drug products. Furthermore, no regulatory body has approved any peptide for longevity or anti-aging. Every approved peptide drug carries a strict label defining its singular therapeutic indication.
What does it mean if a peptide is on FDA's category 2 list?
Placement on the Category 2 list indicates that the Food and Drug Administration has identified significant safety risks associated with compounding that bulk drug substance. Under interim policies for sections 503A and 503B, substances in Category 2 are identified as presenting potential significant safety risks. For instance, GHRP-6 was added to Category 2 for 503B outsourcing facilities on 29 September 2023 due to risks of immunogenicity, peptide impurities, cortisol elevation, and reduced insulin sensitivity. Category 2 status reflects active administrative concern, differentiating these substances from nominations that were voluntarily withdrawn by their sponsors.
Is BPC-157 FDA approved?
BPC-157 is not FDA approved for any medical indication. The substance has no approved human drug product on the commercial market. On federal compounding records, BPC-157 sits on the table of bulk drug substances nominated but withdrawn by nominators. Being listed on the withdrawn table means the compound is not in active Category 2 restrictions, but it is also not on any list of bulk substances permitted for compounding. Federal documentation current as of 22 April 2026 provides no clinical safety clearance or approval status for BPC-157, and the agency does not recognize it as an approved drug.